Proteasome Inhibitor plus IMiD or HDAC Inhibitor Regimens in R/R Myeloma Management

Please Log In or Register to continue.

Release Date: July 13, 2016
Expiration Date: July 13, 2017

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The treatment landscape for relapsed/refractory multiple myeloma (MM) is evolving with the availability of new therapies, including the third-generation immunomodulatory drug pomalidomide, and the histone deacetylase inhibitor panobinostat. These new therapies present a challenge to community oncologists who must determine how to incorporate these drugs into clinical practice. Dr. Antonio Palumbo, Associate Professor of Clinical Hematology and Director of the Myeloma Program at the University of Torino, provides an overview of the most recent data supporting the use of pomalidomide and panobinostat in proteasome inhibitor-containing regimens, and shares clinical expertise in managing patients with relapsed/refractory MM who receive these therapies.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Recall dose schedules for triple-agent regimens comprising either of the currently available proteasome inhibitors plus third-generation IMiD plus dexamethasone, or the approved combination of proteasome inhibitor plus HDAC inhibitor plus dexamethasone
  • Compare and contrast which patients may benefit from PAN-BTZ-Dex, Car-Pom-Dex or POM-BORT-LoDEX regimens in the relapsed/refractory disease setting
  • Identify efficacy and safety signatures for discussed regimens, and mitigation strategies which may reduce the frequency or severity of their occurrence

Agenda

Integrating Proteasome Inhibitor Plus Either Third-Generation IMiD or Histone Deacetylase Inhibitor-Based Regimens into Relapsed/Refractory Multiple Myeloma Management – Antonio Palumbo, MD

Instructions for Participation and Credit

This activity is eligible for credit through July 13, 2017. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Antonio Palumbo, MD
Associate Professor of Clinical Hematology
Director, Myeloma Program
Department of Oncology
University of Torino
Torino, Italy

Dr. Antonio Palumbo received his medical degree from the University of Torino, Italy, where he served his residency in internal medicine and held a fellowship in hematology/oncology. He is an Associate Professor of Clinical Hematology, and Director of the Myeloma Program, Department of Oncology at University of Torino. He is also a visiting physician at University of Texas MD Anderson Cancer Center in Houston.

In addition to membership in numerous professional organizations, including the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES), European Society of Medical Oncology (ESMO), European Society of Hematology (EHA), American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), Dr. Palumbo is on the Board of Directors of the International Myeloma Society. He has authored more than 400 publications in peer-reviewed journals as well numerous abstracts and several textbook chapters. Dr. Palumbo specializes in malignant hematology and medical oncology and has clinical and research interest in plasma cell dyscrasia, his current research focuses on the pathogenesis and treatment of multiple myeloma.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-090-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Antonio Palumbo has received honoraria related to speakers’ bureau activities from Bristol-Myers Squibb Company. He has received grant support related to research activities as well as honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, Genmab A/S, Janssen-Cilag Ltd., Merck & Co., Inc., Novartis AG, sanofi-aventis U.S. LLC, and Takeda Oncology.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Palumbo has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Palumbo has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Amgen Inc.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.